Analysis on the efficacy of infliximab in treatment of intestinal Behçet's disease in children
LI Chao
DENG Jianghong
WANG Jiang
KUANG Weiying
ZHANG Junmei
TAN Xiaohua
LI Shipeng
LI Caifeng
Abstract：Objective To analyze the efficacy of infliximab in treatment of intestinal Behçet's disease in children.Methods The clinical data of 10 pediatric patients with intestinal Behçet's disease who were admitted to the Department of Rheumatology of Beijing Children's Hospital,Capital Medical University from January 2017 to December 2020 were retrospectively analyzed.All the pediatric patients were treated with infliximab more than 3 times.The involvement of digestive tract and other systems in the pediatric patients with intestinal Behçet's disease,the treatment of hormones and immunosuppressants,the application of infliximab and follow-up results were explored.Results Among the 10 pediatric patients,7 cases were male and 3 cases were female.The age of the pediatric patients with onset was(8.18±3.66)years,and the median duration of disease was 3(1-72)months.All the 10 pediatric patients had digestive symptoms,including diarrhea in 6 cases,abdominal pain in 5 cases,bloody stool in 3 cases,vomiting in 1 case,abdominal distension in 1 case,and intestinal perforation in 3 cases.Digestive tract ultrasound and endoscopy indicated that ileocecal ulcer was the most common.There were 3 cases with concomitant vascular involvement.The dose of infliximab was 3-5 mg/(kg·per time).The duration of infliximab treatment was(20.9±9.5)months.The median follow-up time of the 10 pediatric patients was 17.5(14-54)months.Nine pediatric patients received methylprednisolone pulse therapy.The initial dose of prednisone was 1.6-2.0 mg/(kg·d).Methotrexate was used in 8 cases,cyclosporine A in 5 cases,thalidomide in 5 cases,and mycophenolate mofetil in 1 case.After treatment,all the pediatric patients had no clinical symptoms,and their inflam-matory indicators and gastrointestinal ultrasound were normal,and their condition was stable.Infliximab was discon-tinued in 6 cases.There were no allergic reactions or active infections during the infusion of infliximab.Conclusion Infliximab is a well-tolerated and effective treatment for children with intestinal Behçet's disease.
Keywords：ChildrenIntestinal Behçet's diseaseInfliximab
Publication Date：2024-09-28
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 967-971 )